ALK2 (R206H)
Sign in to save this workspaceACVR1 · Variant type: point · HGVS: p.R206H
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pacritinib | 89.5% | 10.5% | 88.64 |
| 2 | Dabrafenib | 64.8% | 35.2% | 94.74 |
| 3 | Fedratinib | 59.4% | 40.6% | 96.21 |
| 4 | Crizotinib | 32.1% | 67.9% | 91.39 |
| 5 | Nintedanib | 26.4% | 73.6% | 90.23 |
| 6 | Quizartinib | 22.5% | 77.5% | 99.50 |
| 7 | Temsirolimus | 21.8% | 78.2% | 100.00 |
| 8 | Cabozantinib | 21.2% | 78.8% | 92.73 |
| 9 | Everolimus | 18.2% | 81.8% | 100.00 |
| 10 | Regorafenib | 16.2% | 83.8% | 95.99 |
| 11 | Remibrutinib | 15.0% | 85.0% | 99.50 |
| 12 | Tofacitinib | 12.8% | 87.2% | 99.25 |
| 13 | Ruxolitinib | 10.0% | 90.0% | 98.25 |
| 14 | Dasatinib | 9.7% | 90.3% | 87.97 |
| 15 | Darovasertib | 8.8% | 91.2% | 96.99 |
| 16 | Inavolisib | 8.7% | 91.3% | 100.00 |
| 17 | Dacomitinib | 8.6% | 91.4% | 97.99 |
| 18 | Gilteritinib | 8.5% | 91.5% | 88.97 |
| 19 | Lapatinib | 7.8% | 92.2% | 99.25 |
| 20 | Leniolisib | 7.7% | 92.3% | 100.00 |
| 21 | Paxalisib | 7.4% | 92.6% | 99.75 |
| 22 | Pralsetinib | 6.5% | 93.5% | 93.43 |
| 23 | Selumetinib | 6.1% | 93.9% | 100.00 |
| 24 | Pexidartinib | 5.7% | 94.3% | 99.49 |
| 25 | Deucravacitinib | 5.6% | 94.4% | 98.99 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pacritinib | 89.5% | — | — |
| Dabrafenib | 64.8% | — | — |
| Fedratinib | 59.4% | — | — |
| Crizotinib | 32.1% | — | — |
| Nintedanib | 26.4% | — | — |
| Quizartinib | 22.5% | — | — |
| Temsirolimus | 21.8% | — | — |
| Cabozantinib | 21.2% | — | — |
| Everolimus | 18.2% | — | — |
| Regorafenib | 16.2% | — | — |
| Remibrutinib | 15.0% | — | — |
| Tofacitinib | 12.8% | — | — |
| Ruxolitinib | 10.0% | — | — |
| Dasatinib | 9.7% | — | — |
| Darovasertib | 8.8% | — | — |
| Inavolisib | 8.7% | — | — |
| Dacomitinib | 8.6% | — | — |
| Gilteritinib | 8.5% | — | — |
| Lapatinib | 7.8% | — | — |
| Leniolisib | 7.7% | — | — |
| Paxalisib | 7.4% | — | — |
| Pralsetinib | 6.5% | — | — |
| Selumetinib | 6.1% | — | — |
| Pexidartinib | 5.7% | — | — |
| Deucravacitinib | 5.6% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 31.4ms